# Functional PET for mapping metabolic dynamics in Parkinson’s disease

**Authors:** Vanessa Heinecke, Lilly Machholz, Kenan Steidel, Lenna M. Rüsing, Falk K. Thiemig, Damiano Librizzi, Maya Beckersjürgen, Jennifer Fuchs, Markus Luster, Lars Timmermann, David Pedrosa, Marina C. Ruppert-Junck

PMC · DOI: 10.1038/s41598-025-28456-x · 2025-11-18

## TL;DR

This study uses a new PET method to track metabolic changes in Parkinson’s disease, revealing dynamic patterns linked to cognitive symptoms.

## Contribution

A novel dynamic PET protocol combined with MRI to map individual metabolic dynamics in Parkinson’s disease.

## Key findings

- PD patients showed hypometabolism in the substantia nigra compared to controls.
- Region-specific increases in time series variation correlated with cognitive PD symptoms.
- The method enabled visualization of metabolic networks in basal ganglia and resting-state circuits.

## Abstract

Static [18F]-FDG PET studies have shown characteristic metabolic patterns for Parkinson’s disease (PD). However static PET scans offer only a snapshot of synaptic activity, preventing insights into dynamics of glucose consumption on individual level. In this study, we apply a novel dynamic constant infusion PET protocol in combination with MRI for mapping metabolic dynamics in PD. Metabolic time series comparison revealed hypometabolism in bilateral clusters in the substantia nigra in PD patients compared to controls (pFWE < 0.001). The temporal structure allowed us to depict metabolic networks covering the basal ganglia circuits and typical neural resting-state networks on individual level. A measure of time series variation showed a region-specific increase in time series variation in PD, which related to cognitive PD symptoms. The findings pinpoint the methodological capabilities of the acquisition protocol for evaluating metabolic dynamics and metabolic network activity on subject-level in PD. Our study lays a foundation for the application of molecular imaging with temporal resolution in context of neurodegenerative diseases. Such protocols can capture interregional metabolic changes on patient level, the applicability of which should be evaluated in prodromal stages.

The online version contains supplementary material available at 10.1038/s41598-025-28456-x.

## Linked entities

- **Chemicals:** [18F]-FDG (PubChem CID 68614)
- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Diseases:** neurodegenerative diseases (MESH:D019636), PD (MESH:D010300)
- **Chemicals:** [18F]-FDG (MESH:D019788), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12627653/full.md

---
Source: https://tomesphere.com/paper/PMC12627653